神経内分泌腫瘍治療市場：現状分析・予測 (2022年～2028年)

世界の神経内分泌腫瘍治療の市場規模は予測期間中に約10％という著しい成長を遂げると予想されています。

予測期間中は神経内分泌腫瘍 (NET) の症例数が増加することで、さまざまな治療オプションに対する需要が加速すると予想されています。新しい診断法や治療法の開発に伴い、この分野は急速に発展しています。需要の高いNET治療市場は、主にラジオ波焼灼療法やGa標識ラジオヌクレオチド療法などの検出方法に関するR&Dの継続的な取り組みによって牽引されています。

地域別で見ると、北米が市場をリードしています。これは主に、医療インフラが整備されていること、医療従事者の数が多いことなどが要因です。さらに、同地域における胃神経内分泌腫瘍、肺神経内分泌腫瘍、膵神経内分泌腫瘍、カルチノイド腫瘍の症例数が増加していることも市場の成長を後押ししています。

当レポートでは、世界の神経内分泌腫瘍治療の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、需給動向、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法・前提因子

第3章 市場概要

第4章 エグゼクティブサマリー

第5章 COVID-19：神経内分泌腫瘍治療市場への影響

第6章 神経内分泌腫瘍治療市場：収益の推移・予測

第7章 市場洞察：製品別

• ソマトスタチン類似体（SSA）
• 標的療法
• 化学療法
• その他

第8章 市場洞察：適応症別

• 肺
• 膵臓
• 胃腸
• その他

第9章 市場洞察：エンドユーザー別

• 病院
• 診療所
• その他

第10章 市場洞察：地域別

• 北米
• 欧州
• アジア太平洋
• その他の地域

第11章 神経内分泌腫瘍治療市場：市場力学

• 市場促進要因
• 市場課題
• 影響分析

第12章 神経内分泌腫瘍治療市場：市場機会

第13章 神経内分泌腫瘍治療市場：市場動向

第14章 需要サイド・供給サイドの分析

• 需要サイド分析
• 供給サイド分析

第15章 バリューチェーン分析

第16章 競合シナリオ

第17章 企業プロファイル

• Pfizer Inc.
• Novartis AG
• Chiasma Inc.
• Ipsen
• Abbvie Inc.
• Valeant Pharmaceuticals International Inc.
• Jubilant Life Sciences Ltd.
• Teva Pharmaceutical Industries Ltd
• F. Hoffmann-La Roche Ltd
• Advanced Accelerator Applications

第18章 免責事項

The global neuroendocrine tumor treatment market is expected to grow at a significant rate of around 10% during the forecast period. Over the course of the forecast period, an increase in the number of cases of neuroendocrine tumors (NETs) is anticipated to accelerate the demand for various treatment options. As new diagnostics and therapies are developed, this is a rapidly developing field. The demand NET treatment market is primarily driven by ongoing R&D efforts in detection methods like radiofrequency ablation and Ga-labeled radionucleotide therapies.

For instance, Progenics Pharmaceuticals, Inc.'s PSMA Targeted PET Imaging Agent, for instance, is currently in the clinical trial phase and is anticipated to aid in the treatment of prostate cancer. Another important factor driving the expansion of the NET market is the substantial investment in the field made by cancer research organizations and governments worldwide.

Pfizer Inc., Novartis AG, Chiasma Inc., Ipsen, Abbvie Inc., Valeant Pharmaceuticals International Inc., Jubilant Life Sciences Ltd., Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., and Advanced Accelerator Applications. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst indication, gastrointestinal category to witness robust CAGR during the forecast period"

Based on type, the market is segmented into lungs, pancreas, gastrointestinal, and others. Among them, the gastrointestinal category is to witness the highest CAGR during the forecast period owing to the more number of patients seen for gastric neuroendocrine growths so there is developing prominence and driving this segment.

Moreover, the pancreas portion is supposed to have consistent development during the following couple of years. The expansion of the market is anticipated to be aided by an increase in R&D expenditures for the creation of novel therapies for pancreatic NETs.Pfizer Inc.'s SUNITINIB is being tested in a phase III clinical trial for the treatment of NETs in the pancreas.

"Amongst end-user, the hospitals to hold a significant share in the market in 2020"

On the basis of drive type, the market is categorized into hospitals, clinics, and others. Among these, the hospitals category to hold a significant share of the market in 2020. This is mainly due to these facilities being used for a lot of diagnostic procedures, a large number of patients treated at hospitals, and the availability of trained professionals. The segment's expansion is anticipated to be further bolstered by the availability of numerous NET diagnosis options and developed technologies.

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the cardiac monitoring industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America); Europe (Germany, United Kingdom, France, Spain, Italy, Rest of Europe); Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific); and the Rest of World. North American region helped the region to obtain a dominating position in the market. This is mainly due to the well-settled healthcare infrastructure, and availability of medical professionals. Furthermore, rising cases of gastric neuroendocrine tumors, lung neuroendocrine tumors, pancreatic neuroendocrine tumors, and carcinoid tumors in the region are the propel the growth of the market. For instance, carcinoid tumor affects between 3,000 and 30,000 people in the United States, according to data updated in 2021 by the National Center for Advancing Translational Sciences Genetic and Rare Diseases Information Center. These tumors typically originate in the gastrointestinal tract or the lungs. It is anticipated that the market will expand as a result of the widespread incidence of neuroendocrine cancer in the region.  

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global neuroendocrine tumor treatment market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Neuroendocrine Tumor Treatment Market
• 2.2. Research Methodology of the Neuroendocrine Tumor Treatment Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE NEUROENDOCRINE TUMOR TREATMENT MARKET

6 NEUROENDOCRINE TUMOR TREATMENT MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY PRODUCTS

• 7.1. Somatostatin Analogs (SSAs)
• 7.2. Targeted Therapy
• 7.3. Chemotherapy
• 7.4. Others

8 MARKET INSIGHTS BY INDICATION

• 8.1. Lungs
• 8.2. Pancreas
• 8.3. Gastrointestinal
• 8.4. Others

9 MARKET INSIGHTS BY END USER

• 9.1. Hospitals
• 9.2. Clinics
• 9.3. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 NEUROENDOCRINE TUMOR TREATMENT MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 NEUROENDOCRINE TUMOR TREATMENT MARKET OPPORTUNITIES

13 NEUROENDOCRINE TUMOR TREATMENT MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1. Pfizer Inc.
• 17.2. Novartis AG
• 17.3. Chiasma Inc.
• 17.4. Ipsen
• 17.5. Abbvie Inc.
• 17.6. Valeant Pharmaceuticals International Inc.
• 17.7. Jubilant Life Sciences Ltd.
• 17.8. Teva Pharmaceutical Industries Ltd
• 17.9. F. Hoffmann-La Roche Ltd
• 17.10. Advanced Accelerator Applications

18 DISCLAIMER